Corvus Pharma Com (CRVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2020 | 09-2020 | 06-2020 | 03-2020 | 12-2019 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -5,995 | -33,342 | -23,546 | -12,935 | -46,672 |
| Depreciation Amortization | 786 | 534 | 275 | 120 | 99 |
| Accounts payable and accrued liabilities | 1,019 | 123 | 331 | 908 | 450 |
| Other Working Capital | 1,909 | 1,726 | 1,204 | 1,617 | 1,904 |
| Other Operating Activity | -32,497 | 4,388 | 2,897 | 937 | 6,898 |
| Operating Cash Flow | $-34,778 | $-26,571 | $-18,839 | $-9,353 | $-37,321 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 44,845 | 44,382 | 34,367 | 27,697 | 3,280 |
| PPE Investments | -76 | -76 | N/A | N/A | -25 |
| Investing Cash Flow | $44,769 | $44,306 | $34,367 | $27,697 | $3,255 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 1,310 | 87 | 23 | N/A | 24 |
| Financing Cash Flow | $1,310 | $87 | $23 | $N/A | $24 |
| Beginning Cash Position | 5,154 | 5,154 | 5,154 | 5,154 | 39,196 |
| End Cash Position | 16,455 | 22,976 | 20,705 | 23,498 | 5,154 |
| Net Cash Flow | $11,301 | $17,822 | $15,551 | $18,344 | $-34,042 |
| Free Cash Flow | |||||
| Operating Cash Flow | -34,778 | -26,571 | -18,839 | -9,353 | -37,321 |
| Capital Expenditure | -76 | -76 | N/A | N/A | -25 |
| Free Cash Flow | -34,854 | -26,647 | -18,839 | -9,353 | -37,346 |